KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Repurchased
Ratios

Pacira BioSciences (PCRX) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Pacira BioSciences (PCRX) over the last 17 years, with Q3 2025 value amounting to $69.7 million.

  • Pacira BioSciences' Accumulated Depreciation & Amortization rose 2109.59% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.7 million, marking a year-over-year increase of 2109.59%. This contributed to the annual value of $78.8 million for FY2024, which is 424.88% up from last year.
  • As of Q3 2025, Pacira BioSciences' Accumulated Depreciation & Amortization stood at $69.7 million, which was up 2109.59% from $48.5 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Accumulated Depreciation & Amortization ranged from a high of $91.5 million in Q4 2022 and a low of $4.9 million during Q1 2021
  • In the last 5 years, Pacira BioSciences' Accumulated Depreciation & Amortization had a median value of $38.7 million in 2023 and averaged $41.8 million.
  • As far as peak fluctuations go, Pacira BioSciences' Accumulated Depreciation & Amortization skyrocketed by 31954.25% in 2022, and later crashed by 1740.64% in 2023.
  • Over the past 5 years, Pacira BioSciences' Accumulated Depreciation & Amortization (Quarter) stood at $28.5 million in 2021, then soared by 220.52% to $91.5 million in 2022, then dropped by 17.41% to $75.6 million in 2023, then increased by 4.25% to $78.8 million in 2024, then fell by 11.56% to $69.7 million in 2025.
  • Its last three reported values are $69.7 million in Q3 2025, $48.5 million for Q2 2025, and $21.2 million during Q1 2025.